TOT BIOPHARM INTERNA

1875
End-of-day quote. End-of-day quote  - 01/28
3.62HKD +0.28%

TOT BIOPHARM International : CERTAIN UNAUDITED FINANCIAL INFORMATION FOR THE THREE MONTHS ENDED 31 MARCH 2021

05/10/2021 | 07:48am

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

TOT BIOPHARM International Company Limited

東曜藥業股份有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1875)

CERTAIN UNAUDITED FINANCIAL INFORMATION

FOR THE THREE MONTHS ENDED 31 MARCH 2021

This announcement is made by TOT BIOPHARM International Company Limited (the "Company", together with its subsidiaries, the "Group") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Pursuant to applicable disclosure requirements of the Taipei Exchange in Taiwan, Center Laboratories Inc. (the Company's controlling shareholder whose shares are listed on the Taipei Exchange in Taiwan) is required to disclose, on a date which is expected to be on or before 15 May 2021, certain unaudited consolidated financial information of the Group for the three months ended 31 March 2021.

In order to facilitate timely dissemination of information to investors and potential investors in Hong Kong and Taiwan, the Company's board of directors (the "Board") would like to inform the Company's shareholders and potential investors of the following unaudited consolidated financial information of the Group for the three months ended 31 March 2021, which is extracted from the Group's latest unaudited management accounts and other information currently available.

IMPORTANT

As mentioned above, the Group's results for the three months ended 31 March 2021 set out in this announcement are unaudited. The Group's results of operations in the past have fluctuated and may in the future continue to fluctuate from one period to another period. Accordingly, the Group's results of operations for any period should not be considered to be indicative of the results to be expected for any future period. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the securities of the Company.

During the three months ended 31 March 2021, the Group's revenue increased by 99.8% year-on-year to RMB14,584,000, mainly attributable to the increase in CDMO business and the milestone payment income from monoclonal antibody drug TAB014.

- 1 -

CONDENSED CONSOLIDATED BALANCE SHEET

As at

As at

31 March

31 December

2021

2020

RMB'000

RMB'000

(unaudited)

(audited)

Current assets

200,300

249,227

Non-current assets

403,260

391,956

Current liabilities

(55,517)

(52,743)

Non-current liabilities

(4,546)

(6,083)

Total net assets

543,497

582,357

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE LOSS

For the

For the

period from

period from

1 January 2021 to

1 January 2020 to

31 March 2021

31 March 2020

RMB'000

RMB'000

(unaudited)

(unaudited)

Revenue

14,584

7,300

Net loss

(42,715)

(58,367)

Other comprehensive income

387

4,606

Total comprehensive loss for the period

(42,328)

(53,761)

The above information is subject to possible adjustments following further internal review, and is not based on any figure(s) or information which has/have been reviewed by the Company's external auditor or the Audit and Connected Transactions Review Committee.

By order of the Board

TOT BIOPHARM International Company Limited

Dr. Liu, Jun

Chief Executive Officer and Executive Director

Hong Kong, 10 May 2021

As at the date of this announcement, the executive directors of the Company are Ms. Yeh- Huang, Chun-Ying and Dr. Liu, Jun; the non-executive directors of the Company are Mr. Fu, Shan, Dr. Kung, Frank Fang-Chien, Mr. Kang, Pei and Mr. Qiu, Yu Min; and the independent non-executive directors of the Company are Ms. Hu, Lan, Dr. Sun, Lijun Richard and Mr. Chang, Hong-Jen.

- 2 -

Disclaimer

TOT BIOPHARM International Co. Ltd. published this content on 10 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 May 2021 11:47:04 UTC.

© Publicnow 2022
Copier lien
All news about TOT BIOPHARM INTERNATIONAL COMPANY LIMITED
01/12
01/03
12/08
12/01
12/01